Live price temporarily unavailable.
Orchestra BioMed Holdings (OBIO) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $3.53M | $2.76M | $2.64M | $33.5M |
| Growth (year over year) | — | — | −21.9% | −4.4% | +1169.2% |
| Gross profit | — | $3.32M | $2.57M | $2.43M | $33.3M |
| Gross margin | — | 94.0% | 93.3% | 92.3% | 99.4% |
| Operating income | −$394.8K | −$32.7M | −$51.5M | −$64.3M | −$51.8M |
| Operating margin | — | −924.3% | −1866.2% | −2437.5% | −154.7% |
| Net income | −$378.8K | −$33.6M | −$49.1M | −$61.0M | −$52.7M |
| Net margin | — | −951.3% | −1779.7% | −2313.3% | −157.4% |
| EPS (diluted) | −$0.02 | −$2.24 | −$1.48 | −$1.66 | −$1.11 |
| Balance sheet | |||||
| Cash and equivalents | $1.75M | $19.8M | $30.6M | $22.3M | $34.7M |
| Total assets | $161.8M | $95.6M | $95.2M | $76.2M | $114.9M |
| Total liabilities | $5.77M | $43.0M | $27.2M | $43.2M | $51.5M |
| Long-term debt | — | — | — | $15.0M | $15.0M |
| Shareholders' equity | −$19.8M | $52.5M | $68.0M | $33.0M | $53.6M |
| Cash flow | |||||
| Operating cash flow | −$272.4K | −$29.3M | −$46.1M | −$50.6M | −$49.0M |
| Capital expenditure | — | $591.0K | $78.0K | $289.0K | $489.0K |
| Free cash flow | — | −$29.9M | −$46.2M | −$50.8M | −$49.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $987.0K | $253.0K | $868.0K | $836.0K | $861.0K | — | $110.0K | $88.0K |
| Growth (year over year) | +135.6% | −3.4% | +40.0% | +7.5% | −12.8% | — | −87.3% | −89.5% |
| Gross profit | $919.0K | $195.0K | $824.0K | $790.0K | $812.0K | — | $78.0K | $63.0K |
| Gross margin | 93.1% | 77.1% | 94.9% | 94.5% | 94.3% | — | 70.9% | 71.6% |
| Operating income | −$16.3M | −$16.7M | −$18.9M | −$19.3M | −$20.3M | — | −$22.1M | −$22.4M |
| Operating margin | −1655.7% | −6591.7% | −2179.8% | −2311.8% | −2359.2% | — | −20069.1% | −25404.5% |
| Net income | −$15.4M | −$16.2M | −$18.8M | −$19.4M | −$20.8M | — | −$20.7M | −$23.8M |
| Net margin | −1562.9% | −6385.4% | −2160.7% | −2316.1% | −2419.0% | — | −18810.0% | −26994.3% |
| EPS (diluted) | −$0.41 | −$0.42 | −$0.49 | −$0.50 | −$0.40 | — | −$0.33 | −$0.38 |
| Balance sheet | ||||||||
| Cash and equivalents | $25.6M | $22.3M | $18.3M | $18.7M | $42.0M | $34.7M | $28.4M | $20.5M |
| Total assets | $75.3M | $76.2M | $59.1M | $42.8M | $104.8M | $114.9M | $100.7M | $115.7M |
| Total liabilities | $29.1M | $43.2M | $42.2M | $42.5M | $61.1M | $51.5M | $49.7M | $86.3M |
| Long-term debt | — | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | — |
| Shareholders' equity | $46.2M | $33.0M | $16.9M | $295.0K | $43.7M | $53.6M | $41.2M | $19.3M |
| Cash flow | ||||||||
| Operating cash flow | −$13.7M | −$13.5M | −$16.6M | −$15.5M | −$14.6M | — | −$22.2M | −$19.3M |
| Capital expenditure | $68.0K | $106.0K | $112.0K | $34.0K | $310.0K | — | $184.0K | $254.0K |
| Free cash flow | −$13.8M | −$13.6M | −$16.7M | −$15.6M | −$14.9M | — | −$22.4M | −$19.6M |
From Orchestra BioMed Holdings's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Orchestra BioMed Holdings in our feed yet.